Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
- R. Kahn, W. Fleischhacker, D. Grobbee
- Psychology, MedicineThe Lancet
- 29 March 2008
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
- W. Fleischhacker, M. Eerdekens, O. Gefvert
- Psychology, MedicineJournal of Clinical Psychiatry
- 1 October 2003
In terms of both safety and efficacy, symptomatically stable patients with schizophrenia benefit from being switched to long-acting injectable risperidone, and Severity of symptoms of schizophrenia was improved in each group.
Metabolic side effects of antipsychotic medication
- A. Tschoner, J. Engl, C. Ebenbichler
- MedicineInternational journal of clinical practice
- 1 August 2007
The use of second‐generation antipsychotics is associated with metabolic side effects including weight gain, diabetes mellitus and an atherogenic lipid profile, which may also impair the patient's adherence to treatment.
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
- J. Kane, R. Sanchez, W. Fleischhacker
- Psychology, MedicineJournal of Clinical Psychiatry
- 15 May 2012
Aripiprazole-IM-depot significantly delayed time to impending relapse compared with placebo and appears to be a well-tolerated maintenance treatment option for schizophrenia.
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
- A. Savitz, Haiyan Xu, W. Fleischhacker
- Medicine, PsychologyInternational Journal of Neuropsychopharmacology
- 22 February 2016
PP3M was noninferior to PP1M: relapse rates were similar in both groups and increased weight was the most common treatment-emergent adverse event (double-blind phase; 21% each).
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
- R. Tandon, R. Belmaker, H. Moeller
- Psychology, MedicineSchizophrenia Research
- 1 March 2008
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study
- W. Fleischhacker, R. Sanchez, J. Kane
- Medicine, PsychologyBritish Journal of Psychiatry
- 1 August 2014
Aripiprazole once-monthly 400mg was non-inferior to oral aripipazole, and the reduction in Kaplan–Meier estimated impending relapse rate at week 26 was statistically significant.
Compliance with antipsychotic treatment
- M. Oehl, M. Hummer, W. Fleischhacker
- Medicine, PsychologyActa Psychiatrica Scandinavica Supplementum
- 1 December 2000
Different factors influencing compliance are reviewed and possibilities to enhance compliance among schizophrenic patients are discussed.
Use of alternative / complementary therapy in breast cancer patients – a psychological perspective
- R. Moschèn, G. Kemmler, B. Sperner-Unterweger
- Psychology, MedicineSupportive Care in Cancer
- 30 May 2001
Patients using a large number of alternative therapies tended to adopt a more depressive coping style than those using only a small number, and a subgroup of patients using many alternative therapies seem to have considerable adjustment problems.
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
- W. Fleischhacker, M. Heikkinen, W. Kerselaers
- Medicine, PsychologyInternational Journal of Neuropsychopharmacology
- 1 September 2010
Combining aripiprazole and clozapine resulted in significant weight, BMI and fasting cholesterol benefits to patients suboptimally treated with clozAPine and there were no significant differences in Positive and Negative Syndrome Scale total score changes between groups.
...
...